TORONTO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., ("Arch" or the "Company") (TSXV:ARCH, OTCQB:ACHFF), announced today it has arranged a non-brokered private placement offering of 480,769 common shares priced at $1.04 per common share (the "Common Shares") for gross proceeds of $500,000 CAD (the "Offering").

The proceeds of the Offering will be used by Arch as general working capital and for certain operating expenses that are not covered by the Company's human trial funding grants. The Offering will close on November 12, 2025 and is subject to certain conditions including, but not limited to, the receipt of applicable regulatory approvals, including conditional and final approval from the TSX Venture Exchange, as well as the satisfaction of customary closing conditions.

The Offering will involve the issuance of all 480,769 Common Shares to an officer of the Company and therefore a "related party" (as such term is defined under Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ("MI 61-101")) and therefore constitutes a related party transaction under MI 61-101. This transaction is exempt from the formal valuation and minority shareholder approval requirements of MI 61-101 pursuant to sections 5.5(a) and 5.7(a) of MI 61-101, as the fair market value of the Common Shares distributed and the consideration received from related party in the Private Placement does not exceed 25% of the Company's market capitalization.

All Common Shares issued in connection with the Offering will ...